Novartis to acquire Tourmaline Bio for $1.4 billion
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
Goyal reaffirmed the government’s commitment to facilitating market access, reducing trade barriers, and ensuring that Indian exporters remain globally competitive
Under the partnership, the Pfizer INDovation program will empower DPIIT-recognized startups with grants of up to Rs. 60 lakhs each, along with a tailored 18-month incubation program delivered by Social Alpha
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age
This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Guidelines aim to establish state-regulated veterinary blood banks
Subscribe To Our Newsletter & Stay Updated